Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals

International Journal of Biological Macromolecules

Volumn 86, Issue , 2016, Pages 112-118

  Shang, Qingsen ^a   Yin, Yeshi ^b   Zhu, Liying ^b   Li, Guoyun ^a   Yu, Guangli ^a   Wang, Xin ^b  

^a Laboratory for Marine Science and Technology   (China)

^b INSTITUTE OF PLANT PROTECTION AND MICROBIOLOGY   (China)

Author keywords

Chondroitin sulfate; Clostridium hathewayi; Degradation

Indexed keywords

CHONDROITIN SULFATE;

ADULT; ARTICLE; BACTERIUM ISOLATION; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; CHINESE; CLOSTRIDIUM; CLOSTRIDIUM HATHEWAYI; COMPARATIVE STUDY; CONTROLLED STUDY; DEGRADATION KINETICS; FECES ANALYSIS; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; MICROBIAL ACTIVITY; MICROBIAL CONSORTIUM; NONHUMAN; NORMAL HUMAN; BACTERIUM; BIOAVAILABILITY; DIETARY SUPPLEMENT; FECES; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; YOUNG ADULT;

ADULT; BACTERIA; BIOLOGICAL AVAILABILITY; CHONDROITIN SULFATES; DIETARY SUPPLEMENTS; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 84955504369     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2016.01.055     Document Type: Article

References (54)

1. Miller K.L., Clegg D.O. Glucosamine and chondroitin sulfate. Rheum. Dis. Clin. N. Am. 2011, 37:103-118.
2. March L., Smith E.U., Hoy D.G., Cross M.J., Sanchez-Riera L., Blyth F., Buchbinder R., Vos T., Woolf A.D. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract. Res. Clin. Rheumatol. 2014, 28:353-366.
3. Glyn-Jones S., Palmer A.J.R., Price A.J., Vincent T.L., Weinans H., Carr A.J. Osteoarthritis. Lancet 2015, 9991:376-387.
4. Ronca F., Palmieri L., Panicucci P., Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthr. Cartil. 1998, 6:14-21.
5. ®): the Zurich study. Osteoporos. Int. 2002, 13:S21.
6. Sakai1 S., Otake1 E., Toida1 T., Goda Y. Identification of the origin of chondroitin sulfate in Health Foods. Chem. Pharm. Bull. 2007, 55:299-303.
7. Lauder R.M. Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement. Ther. Med. 2009, 17:56-62.
8. Messier S.P., Mihalko S., Loeser R.F., Legault C., Jolla J., Pfruender J., Prosser B., Adrian A., Williamson J.D. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthr. Cartil. 2007, 15:1256-1266.
9. Baici A., Hörler D., Moser B., Hofer H.O., Fehr K., Wagenhauser F.J. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol. Int. 1992, 12:81-88.
10. Conte A., De Bernardi M., Palmieri L., Lualdi P., Mautone G., Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneim.-Forsch. 1991, 41:768-772.
11. Barthe L., Woodley J., Lavit M., Przybylski C., Philibert C., Houin G. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneim.-Forsch. 2003, 54:286-292.
12. Preidis G.A., Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009, 136:2015-2031.
13. Wilson I.D., Nicholson J.K. The role of gut microbiota in drug response. Curr. Pharm. Des. 2009, 15:1519-1523.
14. Jia W., Li H., Zhao L., Jeremy K.N. Gut microbiota: a potential new territory for drug targeting. Nat. Rev. Drug Discov. 2008, 7:123-129.
15. Wallace B.D., Redinbo M.R. The human microbiome is a source of therapeutic drug targets. Curr. Opin. Chem. Biol. 2013, 17:379-384.
16. Salyers A.A., Vercellotti J.R., West S.E., Wilkins T.D. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl. Environ. Microb. 1977, 33:319-322.
17. Ahn M.Y., Shin K.H., Kim D., Jung E., Toida T., Linhardt R.J., Kim Y.S. Characterization of a Bacteroides species from human intestine that degrades glycosaminoglycans. Can. J. Microbiol. 1998, 44:423-429.
18. Martens E.C., Lowe E.C., Chiang H., Pudlo N.A., Wu M., McNulty N.P., Abbott D.W., Henrissat B., Gilbert H.J., Bolam D.N., Gordon J.I. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PloS Biol. 2011, 9:e1001221.
19. Andermann G., Dietz M. The influence of the route of administration on the bioavailability of an endogenous macromolecule: chondroitin sulphate (CSA). Eur. J. Drug Metab. Pharmacokinet. 1982, 7:11-16.
20. Schiraldi C., Cimini D., Rosa M.D. Production of chondroitin sulfate and chondroitin. Appl. Microbiol. Biotechnol. 2010, 87:1209-1220.
21. Lei F., Yin Y., Wang Y., Deng B., Yu H.D., Li L., Xiang C., Wang S., Zhu B., Wang X. Higher-level production of volatile fatty acids in vitro by chicken gut microbiotas than by human gut microbiotas as determined by functional analyses. Appl. Environ. Microb. 2012, 78:5763-5772.
22. Suez J., Korem T., Zeevi D., Zilberman-Schapira G., Thaiss C.A., Maza O., Israeli D., Zmora N., Gilad S., Weinberger A., Kuperman Y., Harmelin A., Kolodkin-Gal I., Shapiro H., Halpern Z., Segal E., Elinav E. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 2014, 514:181-186.
23. Wang P., Zhao X., Lv Y., Miaomiao L., Xin L., Guangsheng L., Guangli Y. Structural and compositional characteristics of hybrid carrageenans from red algae Chondracanthus Chamissoi. Carbohydr. Polym. 2012, 89:914-919.
24. Terho T.T., Hartiala K. Method for determination of the sulfate content of glycosaminoglycans. Anal. Biochem. 1971, 41:471-476.
25. Li M., Li G., Zhu L., Yin Y., Zhao X., Xiang C., Yu G., Wang X. Isolation and characterization of an agaro-oligosaccharide (AO)-hydrolyzing bacterium from the gut microflora of Chinese individuals. PloS One 2014, 9:e91106.
26. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956, 28:350-356.
27. Franco W., Perez-Diaz I.M., Johanningsmeier S.D., McFeeters R.F. Characteristics of spoilage-associated secondary cucumber fermentation. Appl. Environ. Microb. 2012, 78:1273-1284.
28. Sim J.S., Jun G., Toida T., Cho S.Y., Choi D.W., Chang S.Y., Linhardt R.J., Kim Y.S. Quantitative analysis of chondroitin sulfate in raw materials ophthalmic solutions, soft capsules and liquid preparations. J. Chromatogr. B 2005, 818:133-139.
29. Chassard C., Delmas E., Lawson P.A., Bernalier-Donadille A. Bacteroides xylanisolvens sp. nov., a xylan-degrading bacterium isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2008, 58:1008-1013.
30. Wandel S., Jüni P., Tendal B., Nüesch E., Villiger P.M., Welton N.J., Reichenbach S., Trelle S. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010, 341:c4675.
31. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., Bradley J.D., Bingham C.O., Weisman M.H., Jackson C.G., Lane N.E., Cush J.J., Moreland L.W., Schumacher H.R., Oddis C.V., Wolfe F., Molitor J.A., Yocum D.E., Schnitzer T.J., Furst D.E., Sawitzke A.D., Shi H., Brandt K.D., Moskowitz R.W., Williams H.J. Glucosamine chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 2006, 354:795-808.
32. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., Mende D.R., Li J., Xu J., Li S., Li D., Cao J., Wang B., Liang H., Zheng H., Xie Y., Tap J., Lepage P., Bertalan M., Batto J., Hansen T., Paslier D.L., Linneberg A., Nielsen H.B., Pelletier E., Renault P., Sicheritz-Ponten T., Turner K., Zhu H., Yu C., Li S., Jian M., Zhou Y., Li Y., Zhang X., Li S., Qin N., Yang H., Wang J., Brunak S., Doré J., Guarner F., Kristiansen K., Pedersen O., Parkhill J., Weissenbach J., Consortium M., Bork P., Ehrlich S.D., Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
33. Claesson M.J., Cusack S., O'Sullivan O., Greene-Diniz R., Weerd H., Flannery E., Marchesi J.R., Falush D., Dinan T., Fitzgerald G., Stanton C., Sinderen D., O'Connor M., Harnedy N., O'Connor K., Henry C., O'Mahony D., Fitzgerald A.P., Shanahan F., Twomey C., Hill C., Ross R.P., O'Toole P.W. Composition variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4586-4591.
34. Caporaso J.G., Lauber C.L., Costello E.K., Berg-Lyons D., Gonzalez A., Stombaugh J., Knights D., Gajer P., Ravel J., Fierer N., Gordon J.I., Knight R. Moving pictures of the human microbiome. Genome Biol. 2011, 12:R50.
35. Mikolajczyk A.E., Watson S., Surma B.L., Rubin D.T. Assessment of tandem measurements of pH and total gut transit time in healthy volunteers. Clin. Transl. Gastroenterol. 2015, 6:e100.
36. Ley R.E., Bäckhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11070-11075.
37. Bäckhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:979-984.
38. Turnbaugh1 P.J., Ridaura1 V.K., Faith J.J., Rey F.E., Knight R., Gordon J.I. The effect of diet on the human gut microbiota: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 2009, 1:6ra14.
39. ®) and its constituents in healthy male volunteers. Osteoarthr. Cartil. 2002, 10:768-777.
40. Kusano S., Ootani A., Sakai S., Igarashi N., Takeguchi A., Toyoda H., Toida T. HPLC Determination of chondrosine in mouse blood plasma after intravenous or oral dose. Biol. Pharm. Bull. 2007, 30:1365-1368.
41. Diamant M., Blaak E.E., De Vos W.M. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?. Obesity Rev. 2011, 12:272-281.
42. Steer T., Collins M.D., Gibson G.R., Hippe H., Lawson P.A. Clostridium hathewayi sp. nov., from human faeces. Syst. Appl. Microbiol. 2001, 24:353-357.
43. Woo P.C.Y., Lau S.K.P., Woo G.K.S., Fung A.M.Y., Yiu V.P.Y., Yuen K. Bacteremia due to Clostridium hathewayi in a patient with acute appendicitis. J. Clin. Microbiol. 2004, 42:5947-5949.
44. Linscott A.J., Flamholtz R.B., Shukla D., Song Y., Liu C., Finegold S.M. Fatal septicemia due to Clostridium hathewayi and Campylobacter hominis. Anaerobe 2005, 11:97-98.
45. Randazzo A., Kornreich A., Lissoir B. A Clostridium hathewayi isolate in blood culture of a patient with an acute appendicitis. Anaerobe 2015, 35:44-47.
46. Hallak L.K., Spillmann D., Collins P.L., Peeples M.E. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 2000, 74:10508-10513.
47. Gillet L., Adler H., Stevenson P.G. Glycosaminoglycan interactions in murine gamma herpesvirus-68 infection. PLoS One 2007, 2:e347.
48. Baron M.J., Wong S.L., Nybakken K., Carey V.J., Madoff L.C. Host glycosaminoglycan confers susceptibility to bacterial infection in Drosophila melanogaster. Infect. Immun. 2009, 77:860-866.
49. Jin M., Satsu H., Yamada K., Hisada N., Totsuka M., Shimizu M. Permeation of disaccharides derived from chondroitin sulfate through human intestinal Caco-2 cell monolayers via the paracellular pathway. Biosci. Biotechnol. Biochem. 2010, 74:1243-1249.
50. Ulmer J.E., Vilén E.M., Namburi R.B., Benjdia A., Beneteau J., Malleron A., Bonnaffé D., Driguez P.A., Descroix K., Lassalle G., Narvor C.L., Sandström C., Spillmann D., Berteau O. Characterization of glycosaminoglycan (GAG) sulfatases from the human gut symbiont Bacteroides thetaiotaomicron reveals the first GAG-specific bacterial endosulfatase. J. Biol. Chem. 2014, 289:24289-24303.
51. Ototani N., Yosizawa Z. Purification of chondroitinase B and chondroitinase C using glycosaminoglycan-bound AH-Sepharose 4B. Carbohydr. Res. 1979, 70:295-306.
52. Pojasek K., Shriver Z., Kiley P., Venkataraman G., Sasisekharan R. Recombinant expression purification, and kinetic characterization of chondroitinase AC and chondroitinase B from Flavobacterium heparinum. Biochem. Biophys. Res. Commun. 2001, 286:343-351.
53. Sugahara K., Tanaka Y., Yamada S., Seno N., Kitagawa H., Haslam S.M., Morris H.R., Dell A. Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K unexpected degradation by chondroitinase ABC. J. Biol. Chem. 1996, 271:26745-26754.
54. Ramachandra R., Namburi R.B., Ortega-Martinez O., Shi X., Zaia J., Dupont S.T., Thorndyke M.C., Lindahl U., Spillmann D. Brittlestars contain highly sulfated chondroitin sulfates/dermatan sulfates that promote fibroblast growth factor 2-induced cell signaling. Glycobiology 2014, 24:195-207.